Skip to main content

Errata - English

PDF CSV May 15, 2022 through May 15, 2024 All Errata for USP–NF How to use
Enter the title of the monograph
Monograph Title Sort descending Section Source Publication Page Number Errata Official Date Target Errata Print Publication Target Online Fix Publication Description
CAFFEINE CITRATE ORAL SOLUTION ASSAY/Procedure USP38–NF33 2521 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 5 of Analysis: Change
Result = (rU/rS) × CS × (Mr1/Mr2) × 100
to:
Result = (rU/rS) × C Read More
CAFFEINE CITRATE ORAL SOLUTION Assay USP36–NF31 2733 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 3 of Chromatographic system: Change
150-cm column
to:
15-cm column
CALCIPOTRIENE OINTMENT IMPURITIES/Organic Impurities USP40–NF35 3114 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Footnote a of Table 1: Change
(5Z,7Z,22E,24R)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1α,3β,24-triol.
to:
(5Z,7Z,22E,24S)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1α,3β,24-triol.
CALCIUM ACETATE CAPSULES PERFORMANCE TESTS/Dissolution <711> Revision Bulletin (Official January 01, 2020) Online 1-Mar-2020 NA NA In Test 1/Analysis: Change
dissolved at time point (i):
Resulti = (rU/rS) × CS × V × D × (1/L) × 100
to:
dissolved:
Read More
CALCIUM AND VITAMIN D WITH MINERALS TABLETS STRENGTH USP43–NF38 4845 1-May-2020 NA NA In Calcium, Copper, Magnesium, Manganese, and Zinc, Method 2/Acceptance criteria: Change
NLT 90.0%–125.0%
to:
90.0%–125.0%
CALCIUM ASCORBATE IDENTIFICATION/A. USPNF Online Online 1-Aug-2023 NA NA Change
Characteristic emission lines for calcium at 184.0, 315.9, and 317.9 nm from the Sample solution correspond to those from the Standard solution, as obtained in the Assay.
to:
Characteristic emission lines for calcium at 184.0,… Read More
CALCIUM ASCORBATE ASSAY/Procedure USPNF Online Online 1-Aug-2023 NA NA In Analysis: Change
Mr1 = molecular weight of calcium ascorbate dihydrate, 426.43
to:
Mr1 = molecular weight of calcium ascorbate dihydrate, 426.34
CALCIUM CARBONATE IMPURITIES USP36–NF31 2747 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Acceptance criteria in Limit of Fluoride: Change
50 ppm
to:
NMT 50 ppm
AND
Line 1 of Acceptance criteria in Mercury, Method IIa <261>: Change
0.5 ppm
to:
NMT 0.5 ppm
CALCIUM CARBONATE IMPURITIES/Limit of Magnesium and Alkali Salts USP42–NF37 666 1-Sep-2019 NA NA Change
Sample solution: 1.0 g
to:
Sample: 1.0 g
CALCIUM CITRATE MALATE IMPURITIES/Limit of Fluoride First Supplement to USP41–NF36 8299 1-Jul-2018 USP42–NF37 Second Supplement to USP41–NF36 Line 1 of Standard solution: Change
Transfer 1.0 mL of Standard stock solution
to:
Transfer 2.0 mL of Standard stock solution
CALCIUM GLUCONATE CHEMICAL INFORMATION USP39–NF34 2877 1-Oct-2016 USP41–NF36 First Supplement to USP40–NF35 Line 5: Change
[18016-24-5].
to:
[66905-23-5].
CALCIUM GLUCONATE INJECTION Identification USP37–NF32 2089 1-Oct-2014 USP39–NF34 First Supplement to USP38–NF33 Line 1 of Identification test A: Change
A volume of Injection diluted, if necessary, with water to obtain a test solution of calcium gluconate (1 in 100) responds to Identification test B under Calcium Gluconate.
to:
Dissolve a quantity of it in water to… Read More
CALCIUM GLUCONATE INJECTION DEFINITION USP39–NF34 2879 1-Oct-2016 USP41–NF36 First Supplement to USP40–NF35 Line 8: Change
It may contain sodium hydroxide added for adjustment of the pH.
to:
It may contain sodium hydroxide or hydrochloric acid added for adjustment of the pH.
CALCIUM L-5-METHYLTETRAHYDROFOLATE IDENTIFICATION USPNF Online Online 1-Nov-2022 NA NA In A. Spectroscopic Identification Tests <197>, Infrared Spectroscopy: 197K: Change
USP Calcium DL-5-Methyltetrahydrofolate RS
to:
USP Calcium D,L-5-Methyltetrahydrofolate RS
CALCIUM L-5-METHYLTETRAHYDROFOLATE ASSAY/Procedure USPNF Online Online 1-Nov-2022 NA NA In System suitability solution: Change
USP Calcium DL-5-Methyltetrahydrofolate RS
to:
USP Calcium D,L-5-Methyltetrahydrofolate RS
AND
In Standard solution: Change
USP Calcium DL-5-Methyltetrahydrofolate RS
to:
USP Calcium D,L-5-… Read More
CALCIUM L-5-METHYLTETRAHYDROFOLATE IMPURITIES/Related Compounds USPNF Online Online 1-Nov-2022 NA NA In Analysis: Change
CS = concentration of USP Calcium DL-5-Methyltetrahydrofolate RS in the Standard solution (mg/mL)
to:
CS = concentration of USP Calcium D,L-5-Methyltetrahydrofolate RS in the Read More
CALCIUM L-5-METHYLTETRAHYDROFOLATE IMPURITIES/Enantiomeric Purity USPNF Online Online 1-Nov-2022 NA NA In Standard solution: Change
USP Calcium DL-5-Methyltetrahydrofolate RS
to:
USP Calcium D,L-5-Methyltetrahydrofolate RS
CALCIUM L-5-METHYLTETRAHYDROFOLATE ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USPNF Online Online 1-Nov-2022 NA NA Change
USP Calcium DL-5-Methyltetrahydrofolate RS
to:
USP Calcium D,L-5-Methyltetrahydrofolate RS
CALCIUM LACTATE CHEMICAL INFORMATION USPNF Online Online 1-Apr-2023 NA NA Change
Calcium lactate (1:2) hydrate
to:
Calcium lactate hydrate
AND
Change
Calcium lactate (1:2) pentahydrate
to:
Calcium lactate pentahydrate
CALCIUM LACTATE TABLETS ASSAY/Procedure USP38–NF33 2553 1-Oct-2015 USP40–NF35 First Supplement to USP39–NF34 Line 3 of Analysis: Change
While stirring, add 30 mL of Titrant from a 50-mL buret.
to:
While stirring, add 15 mL of Titrant from a 50-mL buret.
CALCIUM SACCHARATE ASSAY/Procedure USPNF 2021 ISSUE 1 Online 1-Jan-2022 NA NA In Analysis: Change
Result = {[(VSVB) × N × F]/W} × 100
to:
Result = {[(VSVB) × M × F]/W} × 100
AND
Change
Read More
CALCIUM SILICATE IMPURITIES/Limit of Lead USP41–NF36 5240 1-Mar-2019 NA NA In Lead standard solution: Change
1000 mg of lead/mL4
to:
1000 mg of lead/L4
CALCIUM STEARATE IDENTIFICATION USP40–NF35 7557 1-Dec-2017 USP42–NF37 Second Supplement to USP41–NF36 Line 3 of B.: Change
obtained in the Assay.
to:
obtained in the Assay for Content of Stearic Acid and Palmitic Acid.
CALCIUM SULFATE ASSAY/Procedure First Supplement to USP36–NF31 Online 1-Apr-2014 USP38–NF33 USP38–NF33 Line 14 of Analysis: Change
Result = [(V × N × F)/W] × 100
to:
Result = [(V × M × F)/W] × 100
AND
Line 15 of Analysis: Change
V = volume of titrant consumed by the Sample (mL)
N = actual… Read More
CALCIUM SULFATE SPECIFIC TESTS/Loss on Drying <731> USP35–NF30 1724 1-Apr-2013 USP37–NF32 USP37–NF32 Line 1 of Acceptance criteria: Change
NMT 1.5% for the anhydrous form and NMT 19.0%–23.0% for the dihydrate
to:
NMT 1.5% for the anhydrous form and 19.0%–23.0% for the dihydrate
CALCIUM SULFATE ASSAY/Procedure USP35–NF30 1724 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 5 of Titrimetric system: Delete the subsection
Blank: 100 mL of water and 4 mL of 3 N hydrochloric acid
AND
Line 11 of Analysis: Delete the sentence
Perform a blank determination.
AND
Line 13 of Analysis: Change
Result = [(VB… Read More
CALCIUM UNDECYLENATE ASSAY/Procedure USPNF Online Online 1-Nov-2022 NA NA In Solution A: Change
0.15 N hydrochloric acid in water prepared as follows. Transfer 150 mL of hydrochloric acid to a 500-mL volumetric flask, dilute with water to volume, and mix well.
to:
0.15 N hydrochloric acid in water prepared as follows.… Read More
CANDESARTAN CILEXETIL ASSAY/Procedure USP36–NF31 2774 1-Feb-2014 USP38–NF33 Second Supplement to USP37–NF32 Line 1 of Analysis: Change
Titrate with 8 mL of 0.1 N
to:
Titrate with 0.1 N
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS ASSAY/Procedure/Chromatographic system Second Supplement to USP41–NF36 8781 1-Mar-2019 NA NA In Column: Change
[Note—Conditioning of the Column with Solution A and Solution B (80:20)
to:
[Note—Conditioning of the Column with Solution A and Solution B (90:10)
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS IMPURITIES/Organic Impurities USP39–NF34 2895 1-Apr-2016 USP40–NF35 USP40–NF35 Row 3 of Column 1 of Table 6:Change
Candesartan related compound Ab,c
to:
Candesartan cilexetil related compound Ab,c
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS ASSAY/Procedure/Chromatographic system First Supplement to USP42–NF37 Online 1-May-2019 NA NA In Column: Change
4.6-mm × 15-cm; 5-µm packing L7. [Note—Conditioning of the Column with Solution A and Solution B (90:10) (ERR 1-Mar-2019) for about 30 min is recommended prior to use.]
to:
4.6-mm × 15-cm… Read More
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS PERFORMANCE TESTS/Dissolution <711> First Supplement to USP42–NF37 Online 1-May-2019 NA NA In Row 2 of Column 3 of Table 4: Change
0.014/0.028▲2S (USP41)
to:
0.014
AND
In Row 3 of Column 3 of Table 4: Change
0.014
to:
0.014/0.028
AND
In Chromatographic… Read More
CANDESARTAN CILEXETIL TABLETS ADDITIONAL REQUIREMENTS/USP Reference Standards <11> Second Supplement to USP40–NF35 8730 1-Oct-2017 USP42–NF37 First Supplement to USP41–NF36 Line 2 of USP Candesartan Cilexetil Related Compound D RS: Change
1-{[(Cyclohexyloxycarbonyloxy)carbonyl]oxy}ethyl 3-{[2’-(2-ethyl-2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-2-oxo-2,3-dihydro-1H-benzimidazole-4-carboxylate.
to:
1-{[(Cyclohexyloxy)carbonyl]oxy}ethyl 3-({2’-(2-… Read More
CAPRYLIC ACID ASSAY/Procedure/Chromatographic system USP43–NF38 5664 1-May-2020 NA NA In Column: Change
30-cm
to:
30-m
CAPRYLOCAPROYL POLYOXYLGLYCERIDES IMPURITIES/Limit of Free Glycerol USP36–NF31 1922 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Mode in Titrimetric system: Change
Direct titration
to:
Residual titration
AND
Line 10 of Analysis: Change
(VTVB)
to:
(VBVS)
AND… Read More
CAPSICUM OLEORESIN SPECIFIC TESTS/Limit of Nonivamide Second Supplement to USP36–NF31 6577 1-Dec-2013 USP38–NF33 Second Supplement to USP37–NF32 Line 1 of Acceptance criteria: Change
on the dried basis
to:
on the anhydrous basis
CAPTOPRIL ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USPNF 2021 ISSUE 1 Online 1-Dec-2021 NA NA In USP Captopril Disulfide RS: Change
L-Proline, 1,1ʹ-[dithiobis(2-methyl-1-oxo-3,1-propanediyl)]bis-[S-(R*,R*)]-.
to:
(2ʹS)-[(2S,2ʹS)-3,3ʹ-Disulfanediylbis(2-methylpropanoyl)]di-L-proline.
CAPTOPRIL ORAL SOLUTION Assay USP35–NF30 2477 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 1 of Mobile phase: Change
Prepare a filtered and degassed mixture of methanol and water (11:9) containing 0.5 mL of phosphoric acid.
to:
Methanol and water (55:45) containing 0.5 mL/L of phosphoric acid. Filter, and degas.
CAPTOPRIL ORAL SUSPENSION Assay USP35–NF30 2477 1-Feb-2013 USP37–NF32 Second Supplement to USP36–NF31 Line 1 of Mobile phase: Change
Prepare a filtered and degassed mixture of methanol and water (11:9) containing 0.5 mL of phosphoric acid.
to:
Methanol and water (55:45) containing 0.5 mL/L of phosphoric acid. Filter, and degas.
CARAWAY OIL DEFINITION USP36–NF31 1924 1-Jun-2013 USP37–NF32 USP37–NF32 Line 3: Change
It contains NMT 50.0% of d-carvone (C10H14O).
to:
It contains NLT 50.0% of d-carvone (C10H14O).
CARBAMAZEPINE EXTENDED-RELEASE TABLETS ASSAY/Procedure USP37–NF32 2123 1-Jun-2014 USP38–NF33 USP38–NF33 Line 2 of Sample stock solution B: Change
Standard stock solution
to:
Sample stock solution A
CARBAMAZEPINE TABLETS ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USPNF Online Online 1-Jun-2022 NA NA In USP Carbamazepine Related Compound A RS: Change
238.28
to:
238.29
AND
In USP Carbamazepine Related Compound B RS: Change
193.24
to:
193.25
AND
In USP 9-Methylacridine RS: Change
193.24
to:
193.25
CARBIDOPA ASSAY/Procedure USP39–NF34 2924 1-Dec-2016 USP41–NF36 Second Supplement to USP40–NF35 Line 3: Change
Mobile phase: Alcohol and 0.05 M monobasic sodium phosphate, adjusted with phosphoric acid to a pH of 2.7 (5:95)
to:
Buffer: 0.05 M monobasic sodium phosphate, adjusted with phosphoric acid to a pH of 2.7
Mobile phase: Alcohol and Buffer (5:… Read More
CARBIDOPA AND LEVODOPA ORALLY DISINTEGRATING TABLETS ASSAY Second Supplement to USP36–NF31 6580 1-Apr-2014 USP38–NF33 USP38–NF33 Line 2 of Procedure: Change
Inject the Sample solution within 2 h of preparation. Protect the volumetric solutions from light.
to:
Protect the volumetric solutions from light.
CARBIDOPA AND LEVODOPA TABLETS ASSAY/Procedure/Chromatographic system USP41–NF36 693 1-Jun-2018 USP42–NF37 Second Supplement to USP41–NF36 Line 1 of Detector: Change
Identification B,
to:
Identification A,
CARBINOXAMINE MALEATE IMPURITIES/Organic Impurities Second Supplement to USP41–NF36 8786 1-Mar-2019 NA NA In Standard stock solution: Change
(equivalent to 0.05 mg/mL of USP Carbinoxamine Maleate RS free base) and 0.05 mg/mL each of USP Carbinoxamine Related Compound A RS, USP Carbinoxamine Related Compound B RS, and USP Carbinoxamine Related Compound C RS… Read More
CARBINOXAMINE MALEATE TABLETS IMPURITIES/Organic Impurities Second Supplement to USP41–NF36 8788 1-Mar-2019 NA NA In the Standard stock solution: Change
USP Carbinoxamine Maleate RS free base)
to:
carbinoxamine)
AND
In the Standard solution: Change
USP Carbinoxamine Maleate RS free base)
to:
carbinoxamine)
AND
In the Analysis… Read More
CARBOMER COPOLYMER IMPURITIES USPNF 2021 ISSUE 1 Online 1-Jun-2021 NA NA In Limit of Ethyl Acetate and Cyclohexane/Analysis: Change
Samples: Standard stock solution, Standard solution A, Standard solution B, Standard solution C, and Sample solution
to:
Samples: Standard solution A, Standard… Read More
CARBOMER COPOLYMER CHEMICAL INFORMATION USPNF 2021 ISSUE 1 Online 1-May-2021 NA NA See online.uspnf.com for correction
CARBOMER HOMOPOLYMER IMPURITIES USPNF 2021 ISSUE 1 Online 1-Jun-2021 NA NA In Limit of Ethyl Acetate and Cyclohexane/Analysis: Change
Samples: Standard stock solution, Standard solution A, Standard solution B, Standard solution C, and Sample solution
to:
Samples: Standard solution A, Standard… Read More